Carregant...
Dipeptidyl peptidase-4 inhibitors do not increase the risk of cardiovascular events in type 2 diabetes: a cohort study
BACKGROUND: Two recent randomized controlled trials of type 2 diabetes mellitus (T2DM) patients with history of, or at high risk for, cardiovascular disease (CVD) showed no risk of ischemic cardiovascular events associated with dipeptidyl peptidase-4 inhibitors (DPP4i) but an increased risk of heart...
Guardat en:
| Publicat a: | Acta Diabetol |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2014
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4241160/ https://ncbi.nlm.nih.gov/pubmed/25311055 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00592-014-0663-2 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|